Eli Lilly Stock Price Analysis – Earnings Miss And The Pullback Worth Watching
December 06, 2024 at 19:45 PM EST
The company lowered its FY2024 guidance following Q3 earnings, citing supply chain challenges for top-selling drugs like Mounjaro and Zepbound and a one-time R&D expense from its $3.2 billion acquisition of Morphic Holdings.
